- Molecular NameAdenosine
- Synonym2'-Deoxyadenosine; Adenine Deoxy Nucleoside; Adenine Deoxyribonucleoside; Adenine Deoxyribose; Adenine Nucleoside; Adenine Riboside; adenosine; Adenyldeoxyriboside; Deoxyadenosine; Desoxyadenosine; MEDR-640; USAF CB-10
- Weight267.245
- Drugbank_IDDB00640
- ACS_NO58-61-7
- Show 3D model
- LogP (experiment)-1.05
- LogP (predicted, AB/LogP v2.0)-1.22
- pka3.5
- LogD (pH=7, predicted)-1.22
- Solubility (experiment)4.98 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.69
- LogSw (predicted, AB/LogsW2.0)5.27
- Sw (mg/ml) (predicted, ACD/Labs)5.43
- No.of HBond Donors5
- No.of HBond Acceptors9
- No.of Rotatable Bonds2
- TPSA139.54
- StatusFDA approved
- AdministrationIV or injection
- PharmacologyN/A
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding0.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)Erythrocytes transport adenosine from the liver to tissues which cannot synthesise it.
- MetabollsmOnce inside the blood cells, adenosine is phosphorylated, by adenosine kinase, to adenosine monophosphate (AMP). Alternatively, it is deaminated, by adenosine deaminase, to inactive inosine, which can be further degraded to hypoxanthine and then uric acid.
- Half life0.6~10 s
- ExcretionAdenosine is almost completely eliminated after a single pass through the coronary circulation.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe following reactions were reported with intravenous Adenocard (adenosine) used in controlled U.S. clinical trials. The placebo group had a less than 1% rate of all of these reactions. Cardiovascular: Facial flushing (18%), headache (2%), sweating, palpitations, chest pain, hypotension (less than 1%). Respiratory: Shortness of breath / dyspnea (12%), chest pressure (7%), hyperventilation, head pressure (less than 1%). Central Nervous System: Lightheadedness (2%), dizziness, tingling in arms, numbness (1%), apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain (less than 1%). Gastrointestinal: Nausea (3%), metallic taste, tightness in throat, pressure in groin (less than 1%). In post-market clinical experience with Adenocard, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation, and bronchospasm, in association with Adenocard use, have been reported.
- LD50 (rat)N/A
- LD50 (mouse)N/A